Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/173948
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.
Matèries
Matèries (anglès)
Citació
Col·leccions
Citació
PASTICK, Katelyn a., OKAFOR, Elizabeth c., WANG, Fan, LOFGREN, Sarah m., SKIPPER, Caleb p., NICOL, Melanie r., PULLEN, Matthew f., RAJASINGHAM, Radha, MCDONALD, Emily g, LEE, Todd c., SCHWARTZ, Ilan s., KELLY, Lauren e., LOTHER, Sylvain a., MITJÀ VILLAR, Oriol, LETANG, Emilio, ABASSI, Mahsa, BOULWARE, David r.. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). _Open Forum Infectious Diseases_. 2020. Vol. 7, núm. 4. [consulta: 23 de gener de 2026]. ISSN: 2328-8957. [Disponible a: https://hdl.handle.net/2445/173948]